Last Updated: May 11, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

San Marino: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador El Salvador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay World Intellectual Property Organization (WIPO)
Preferred citation:
Friedman, Yali, "San Marino: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: San Marino Patent AP200900001
Patent Title: Polimorfi di n-idrossi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: San Marino Patent P200900001

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: San Marino Patent 201,000,108
Patent Title: Composti e composizioni come inibitori di proteinachinasi.

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: San Marino Patent AP200900058
Patent Title: Composti e composizioni come inibitori di proteinachinasi

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: San Marino Patent P200900058

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: San Marino Patent AP200900099
Patent Title: Composizione a rilascio protratto comprendente un derivato della somatostatina in microparticelle

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: San Marino Patent P200900099
Patent Title: Composizione a rilascio protratto comprendente un derivato della somatostatina in microparticelle.

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: San Marino Patent AP201000002
Patent Title: Sali dell'inibitore di chinasi janus (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazoli-1-il)-3-ciclopentilpropanonitrile

JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: San Marino Patent P201000002
Patent Title: Sali dell'inibitore di chinasi janus (R)-3-(4-(7H-pirrolo[2,3-D]pirimidin-4-IL)-1H-pirazoli-1-IL)-3-ciclopentilpropanonitrile

JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: San Marino Patent AP201000003
Patent Title: Composizione, metodo e preparazione di acidi biliari sintetici

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: San Marino Patent P201000003
Patent Title: Composizione, metodo e preparazione di acidi biliari sintetici

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

San Marino Branded and Generic Drug Markets: Assessment, Regulatory Opportunities, and Challenges

Last updated: January 17, 2026

Summary

San Marino, as a microstate enclave within Italy, presents a unique pharmaceutical market characterized by limited domestic production, high reliance on imports, and a relatively small population (~33,000 as of 2023). The nation’s pharmaceutical sector encompasses both branded and generic drugs, with the regulatory framework aligned closely with European Union standards due to its association with the EU's regulatory influence. This report evaluates the current state of San Marino’s branded and generic drug markets, explores regulatory opportunities, and identifies potential challenges affecting stakeholders.

What Are the Market Characteristics?

Market Size and Demand

Aspect Details
Population ~33,000 (2023)
Gross Domestic Product (GDP) Approximately €790 million (2021 estimate)
Healthcare expenditure ~9.4% of GDP (2021)
Pharmaceutical market value Estimated around €10 million (market share predominantly imports)

Note: The small population constrains the overall drug demand, emphasizing import-driven procurement.

Distribution of Branded vs. Generic Drugs

Drug Type Approximate Market Share Key Features
Branded drugs ~70% Higher price point, marketed by multinational pharma firms
Generic drugs ~30% Cost-efficient, growing presence, regulatory encouragement

The dominance of branded drugs reflects traditional prescribing practices, while generics are gradually gaining acceptance driven by cost-containment policies.

Market Dynamics

  • Import Dependency: San Marino imports over 95% of its pharmaceuticals, primarily from Italy, Switzerland, and the broader EU.
  • Reimbursement System: Mediated through the Azienda sanitaria di San Marino, with coverage extending to both branded and generic drugs.
  • Distribution Channels: Predominantly pharmacies, supplemented by hospital procurement for critical care.

Regulatory Landscape: Opportunities and Challenges

Existing Regulatory Framework

  • Alignments with EU: San Marino follows EU directives, notably Directive 2001/83/EC, with adaptations for local context.
  • Pharmaceutical Authorization: Approval processes involve either mutual recognition or decentralized procedures analogous to the European Medicines Agency (EMA) system.
  • Good Manufacturing Practice (GMP): San Marino enforces GMP standards aligned with EMA and WHO guidelines.

Opportunities in Regulation

Opportunity Details
Harmonization with EU Standards Facilitates drug approvals and imports from EU members, streamlining market access
Adoption of Digital Regulatory Tools Implementing e-submissions and online tracking to improve efficiency
Incentivizing Generics Regulatory incentives—such as expedited review for generic manufacturers—can boost market competition

Regulatory Challenges

Challenge Impact
Limited Local Regulatory Capacity Small regulatory team may limit oversight and innovation
Complex Import Procedures Bureaucratic procedures can delay drug availability
Intellectual Property (IP) Enforcement Potential risks of counterfeit drugs due to weak enforcement mechanisms
Exchange Rate Fluctuations Impacting Imports Currency fluctuations affect pricing and supply stability

Market Entry and Growth Opportunities

For Branded Drugs

  • Innovation and Specialty Drugs: Opportunities exist in niche therapeutic areas such as oncology, rare diseases, and biologics owing to unmet local needs.
  • Partnerships with Local Distributors: Multinational companies can capitalize on existing distribution networks.

For Generic Drugs

  • Cost-Containment Policies: Encouraging substitution policies favoring generics can expand market share.
  • Public Procurement: Simplified procurement processes can facilitate increased usage of generics.
  • Local Production: Potential for establishing small-scale manufacturing units focusing on generic formulations.

Policy Factors Influencing Market Dynamics

Policy Area Effect on Market
Price Regulation Controlled pricing for both branded and generics
Reimbursement Policies Incentivizes or restricts generic utilization
Pharmacovigilance Standards Ensures safety but adds regulatory compliance costs

Comparative Analysis: San Marino vs. Similar Microstates

Aspect San Marino Monaco Vatican City
Population 33,000 39,000 800
Market Size €10 million (approx.) €2 million Minimal
Regulatory Alignment EU standards EU-influenced Vatican-specific policies
Domestic Production Limited None None
Import Dependence High High High

This comparison underscores common challenges and opportunities, such as reliance on imports and alignment with European standards.

Regulatory Opportunities for Stakeholders

Stakeholder Opportunities Actions
Pharmaceutical Companies Market access via EU alignment, niche therapeutic markets Streamline registration, local partnerships
Local Distributors Supply chain optimization, digital tracking Strengthen logistics, compliance systems
Regulatory Authorities Modernize approval processes, adopt digital tools Invest in staff training, e-Government platforms
Policymakers Promote generics, streamline import/export policies Implement incentives, simplify regulations

Challenges for Stakeholders

Stakeholder Challenges Mitigation Strategies
International Pharma Firms Navigating bureaucratic approval, small market size Focus on niche specialty areas
Local Healthcare Providers Limited drug formulary, price pressures Engage in policy dialogue, promote generics
Regulatory Agencies Limited resources, evolving EU regulations Capacity building, regional cooperation

Key Takeaways

  • Market Size and Composition: San Marino’s modest population constrains overall drug market volume, though the market remains lucrative for niche and specialty drugs.
  • Drug Class Distribution: Branded drugs dominate but the generic segment is expanding, driven by cost-containment policies.
  • Regulatory Landscape: Aligns closely with EU standards, presenting both opportunities for streamlined approval and challenges related to resource limitations.
  • Import Dependency: Over 95% of pharmaceuticals are imported, emphasizing the importance of efficient supply chain management.
  • Growth Drivers: Opportunities exist in expanding generic utilization, promoting local manufacturing, and adopting digital regulatory tools.
  • Strategic Recommendations:
    • Strengthen regulatory capacity and digital infrastructure.
    • Foster local partnerships for manufacturing and distribution.
    • Implement policies incentivizing generic substitution.
    • Leverage EU alignment for faster approvals and broader market access.

FAQs

1. How does San Marino’s regulatory framework impact pharmaceutical market entry?

San Marino’s regulation closely mirrors EU directives, easing market access for EU-based companies through mutual recognition and decentralized procedures. However, its small regulatory capacity necessitates local partnerships to navigate approval processes effectively.

2. What are the main barriers to generic drug market growth in San Marino?

Barriers include entrenched prescribing habits favoring branded drugs, regulatory complexity, limited local manufacturing capacity, and reimbursement policies that traditionally favor originator products.

3. How can international pharmaceutical companies capitalize on San Marino’s market?

By focusing on niche therapeutics, biologics, and specialty medicines, and leveraging EU approval pathways. Establishing local partnerships for distribution and adapting to cost-conscious procurement policies enhance market penetration.

4. What is the role of digital regulation in San Marino’s pharmaceutical industry?

Digital tools can improve approval efficiency, pharmacovigilance, and supply chain management. Implementing e-regulatory platforms can reduce administrative burdens and ensure timely drug availability.

5. How is San Marino addressing counterfeit medicines and IP enforcement?

While precise mechanisms are limited given the country’s size, collaboration with neighboring EU jurisdictions and enforcement bodies is ongoing to improve counterfeit detection and IP protection.

References

  1. San Marino Official Portal. (2023). Healthcare and Pharmaceutical Regulations.
  2. European Medicines Agency (EMA). (2022). EU Pharma Regulations Overview.
  3. World Bank. (2021). San Marino Economic Profile.
  4. WHO. (2022). Global MEDICINES SAFETY and Pharmacovigilance Standards.
  5. San Marino Ministry of Health. (2021). National Pharmaceutical Strategy Document.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links